Drug-Device Combination Products: How Regulatory Pathways Differ

A growing share of medical products pair a drug with a device: prefilled syringes carrying a biologic, drug-eluting implants, metered-dose inhalers, autoinjectors and transdermal patches with an embedded delivery mechanism. These drug-device combination products sit at the intersection of two regulatory systems, and which one leads, and how much of each still applies, is decided by specific rules rather than by convenience or marketing. For distributors and institutional buyers, misreading which pathway governs a given product can mean missing a piece of required documentation or assuming a single certificate covers more than it actually does.

What Counts as a Combination Product

A combination product generally falls into one of three structural types: a single-entity product where the drug and device constituents are physically or chemically combined into one unit (a drug-eluting stent, a prefilled autoinjector), a co-packaged product where separate drug and device components are packaged together for use as a system, and a cross-labeled product where separately marketed drug and device products are labeled for use together. The structural type does not by itself determine the regulatory pathway, but it does shape how labeling, packaging and post-market obligations are assessed.

The Core Question: Which Effect Leads

In the United States, the FDA assigns regulatory jurisdiction based on the product's primary mode of action (PMOA), the single mode most responsible for the product's intended therapeutic effect. A lead center, the Center for Drug Evaluation and Research, the Center for Devices and Radiological Health, or the Center for Biologics Evaluation and Research, is designated accordingly, but the product remains subject to combination product rules under 21 CFR Part 3 regardless of which center leads review. The PMOA determination is a formal regulatory decision, not an assumption based on which component seems more prominent to a marketer.

How the EU Framework Differs

Under EU MDR and the parallel medicinal products framework, there is no single designation system comparable to PMOA. Instead, the governing article depends on which role the components play. A device incorporating an ancillary medicinal substance (MDR Article 1(8)) is assessed by a Notified Body, which must still seek a scientific opinion from a medicines authority on the quality, safety and usefulness of that substance. A medicinal product that incorporates a device part as an integral feature (MDR Article 1(9)) is instead evaluated as a whole by the national medicines regulator, with the device element assessed against the relevant General Safety and Performance Requirements. The practical effect is that EU review of a combination product can involve both a Notified Body and a medicines authority working in tandem, even when one of them holds the lead role.

Quality System and Labeling Implications

Because both halves of a combination product carry their own regulatory requirements, the quality system behind one typically has to satisfy both sets of expectations: device-side design controls and risk management, and drug-side good manufacturing practice and stability data for the drug substance. Labeling and instructions for use are expected to address the product as used in combination, including dosing tied to the drug constituent, device-specific handling steps and compatibility and shelf-life data for the assembled product, not only for each constituent considered on its own.

Due Diligence Questions for Distributors and Buyers

A short set of questions tends to reveal whether a supplier's combination-product documentation is complete:

• Which regulatory pathway and lead authority applies to this specific product in each target market, and does the paperwork reflect that?
• Is there a current authorization or certificate for both the drug constituent and the device constituent, not just one?
• Does the labeling and instructions for use address the combination as assembled, rather than treating each component in isolation?
• Are post-market surveillance and adverse-event reporting responsibilities clearly assigned, since a single incident may need reporting through both drug and device vigilance channels?

The Takeaway

Drug-device combination products are not governed by one regulatory category but by whichever framework, or combination of frameworks, matches where the product's primary effect lies, assessed under specific rules that differ between markets. For distributors and buyers, that means checking that documentation covers both the drug and device sides of the product, and confirming which authority or authorities hold current oversight, rather than assuming a single certificate tells the whole story.

This is general educational information, not legal or regulatory advice; consult the current official texts and your competent authority.